Janell M Schelter

US Patent:

8014957, Sep 6, 2011

Filed:

Dec 14, 2006

Appl. No.:

11/640517

Inventors:

Jerald P. Radich - Sammamish WA, US
Hongyue Dai - Kenmore WA, US
Mao Mao - Kirkland WA, US
Janell M. Schelter - Bellevue WA, US
Peter S. Linsley - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA
Rosetta Inpharmatics LLC - Seattle WA

International Classification:

G01N 33/48

US Classification:

702 19, 702 32, 702189, 703 2, 706 18, 435 6, 435 71, 436 63, 436 64

Abstract:

The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

US Patent:

8609830, Dec 17, 2013

Filed:

May 17, 2004

Appl. No.:

10/557219

Inventors:

Aimee L. Jackson - Seattle WA, US
Steven R. Bartz - Seattle WA, US
Julja Burchard - Mount Vernon WA, US
Janell M. Schelter - Bellevue WA, US
Peter S. Linsley - Seattle WA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07H 21/00

US Classification:

536 245, 536 2431, 536 241, 702 19

Abstract:

The invention provides methods and compositions for gene silencing by RNA interference. In particular, the invention provides methods for gene silencing or RNA knockdown using small interfering RNAs (siRNAs) having partial sequence homology to its target gene. The invention also provides methods for identifying common and/or differential responses to a plurality of different siRNAs targeting a gene. The invention also provides methods for evaluating the relative activity of the two strands of an siRNA. The invention further provides methods of designing siRNAs for gene silencing. The invention further provides methods of using siRNAs as therapeutics for treatment of diseases.

US Patent:

20100035966, Feb 11, 2010

Filed:

Jun 14, 2007

Appl. No.:

12/304968

Inventors:

Peter S. Linsley - Seattle WA, US
Janell Schelter - Bellevue WA, US
Julja Burchard - Camano Island WA, US
Lee Lim - Seattle WA, US
Miho Kibukawa - Bothell WA, US

Assignee:

ROSETTA INPHARMATICS LLC - Seattle WA

International Classification:

A61K 31/7105
C12N 5/10
C12Q 1/68
C07H 21/02

US Classification:

514 44 A, 435375, 435 6, 536 245

Abstract:

In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5′ end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell.

US Patent:

20120072124, Mar 22, 2012

Filed:

Aug 10, 2011

Appl. No.:

13/207282

Inventors:

Jerald P. Radich - Sammamish WA, US
Hongyue Dai - Kenmore WA, US
Mao Mao - Kirkland WA, US
Janell M. Schelter - Bellevue WA, US
Peter S. Linsley - Seattle WA, US

International Classification:

G06F 19/20
G01N 33/50

US Classification:

702 20, 702 19

Abstract:

The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

US Patent:

62710028, Aug 7, 2001

Filed:

Oct 4, 1999

Appl. No.:

9/411074

Inventors:

Peter S. Linsley - Seattle WA
Janell M. Schelter - Bellevue WA

Assignee:

Rosetta Inpharmatics, Inc. - Kirkland WA

International Classification:

C12P 1934

US Classification:

435 911

Abstract:

The present invention relates to methods and kits for amplification of mRNA using a primer in PCR that contains an RNA polymerase promoter. The invention provides methods for amplification and detection of RNA derived from a population of cells, preferably eukaryotic cells and most preferably mammalian cells, which methods preserve fidelity with respect to sequence and transcript representation, and additionally enable amplification of extremely small amounts of mRNA, such as might be obtained from 10. sup. 6 mammalian cells. In typical embodiments of the invention, an RNA polymerase promoter (RNAP) is incorporated into ds cDNA by priming cDNA amplification by polymerase chain reaction (PCR) with an RNAP-containing primer. Following less than 20 cycles of PCR, the resultant RNAP-containing ds cDNA is transcribed into RNA using an RNA polymerase capable of binding to the RNAP introduced during cDNA synthesis. This combination of PCR and in vitro transcription (IVT) enables the generation of a relatively large amount of RNA from a small starting number of cells without loss of fidelity.